Fecal Lactoferrin: A New Parameter to Monitor Infliximab Therapy

Author： Buderus Stephan Boone James Lyerly David Lentze Michael J.

ISSN： 0163-2116

Source： Digestive Diseases and Sciences, Vol.49, Iss.6, 2004-06, pp. : 1036-1039

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advantages of Fecal Lactoferrin Measurement during Granulocyte and Monocyte Adsorptive Apheresis Therapy in Ulcerative Colitis

Digestion, Vol. 91, Iss. 3, 2015-03 ,pp. : 208-217

Karger

Access to resources Recommend Favorite

Relationship between fecal lactoferrin and inflammatory bowel disease

By Dai Jun Liu Wen-Zhong Zhao Yong-Ping Hu Yun-Biao Ge Zhi-Zheng

Scandinavian Journal of Gastroenterology, Vol. 42, Iss. 12, 2007-01 ,pp. : 1440-1444

Informa Healthcare

Access to resources Recommend Favorite

New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients

By Tanno Makoto Nakamura Ichiro Kobayashi Shunsuke Kurihara Kumiko Ito Katsumi

Clinical Rheumatology, Vol. 25, Iss. 6, 2006-11 ,pp. : 929-933

Springer Publishing Company

Access to resources Recommend Favorite

Diagnostics and Prognostics of Inflammatory Bowel Disease with Fecal Neutrophil-Derived Biomarkers Calprotectin and Lactoferrin

Digestive Diseases, Vol. 31, Iss. 3-4, 2013-11 ,pp. : 336-344

Karger

Access to resources Recommend Favorite

Severe interstitial pneumonitis associated with infliximab therapy

By Chatterjee S

Scandinavian Journal of Rheumatology, Vol. 33, Iss. 4, 2004-07 ,pp. : 276-277

Informa Healthcare

Access to resources Recommend Favorite